Bulletin
Investor Alert

May 14, 2020, 11:30 a.m. EDT

Novavax (NVAX) And CymaBay Therapeutics (CBAY) Hit 1-Week High On Account Of Affirmative Developments

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Novavax Inc. (NVAX)
  • X
    CymaBay Therapeutics Inc. (CBAY)

or Cancel Already have a watchlist? Log In

May 14, 2020 (The Market Signal via Comtex) -- Sector Reports was created as a platform to help investors find the best free Stock Reports on stocks they own. If you are a shareholder or looking to buy /zigman2/quotes/202614340/composite NVAX +10.86% or /zigman2/quotes/201917619/composite CBAY +2.36% then we strongly urge you to join our community by signing up with the link below and getting a completely free research report on each company today.

http://www.sectorreports.com.au/lP/?symbol=FREE-REPORT

(Click link above or copy, paste and hit enter in your browser for your report)

Open states in the U.S. have started reopening their businesses with consumers willing to come and spend money, bringing a hope that economy will come out of the bondage of COVID-19. With reasonable restrictions and bulwark erected high, mob vigilantism will be an obvious sign of immediate consumer behaviour. In the midst of these, which companies are going a way ahead to ensure that they make shopping and reopening of businesses safe for all? Our article focuses on two healthcare stocks with their one week high on account of optimism.

Novavax Receives Additional $388 Million For Coronavirus Vaccine Funding

https://www.sectorreports.com.au/lP/?symbol=NVAX

(Click link above or copy, paste and hit enter in your browser for your report)

Novavax, Inc. (NASDAQ: NVAX ) was up 137.28% over the last one week. Company's stock has skyrocketed on account of its recent announcement for $388 million approximate funding from Coalition for Epidemic Preparedness or CEPI.

The funding is meant for coronavirus vaccine clinical development. The new candidate of company is called NVX-CoV2373. Funding from CEPI is expected to increase its manufacturing and production of Matrix-M adjuvant, company's proprietary product. Matrix-M adjuvant is expected to help in better immune response of vaccine antigen.

Earlier in March, the company had also received $4 million as initial funding from CEPI to support company's efforts of creating vaccine candidate.

CymaBay Therapeutics Gets Go Ahead From Autonomous Review Panel For Seladelpar Clinical Development

https://www.sectorreports.com.au/lP/?symbol=CBAY

(Click link above or copy, paste and hit enter in your browser for your report)

CymaBay Therapeutics Inc. /zigman2/quotes/201917619/composite CBAY +2.36% was up 127.27% over the last one week. The company recently reported its first quarter 2020 financial results for its quarter ending March 31. Meanwhile, the company also had its Phase 2b study of seladelpar review.

The President and CEO of company, Sujal Shah recently said that in the previous week a panel of some of the hepatologists and liver pathologists, considered to be the best, completed autonomous review of the aforementioned study.

The positive undertone of CEO pushed stock higher with review panel concluding that histological, clinical or biochemical evidence of seladelpar-induced liver injury was no found throughout the study. Resulting this, the panel also supported lifting off clinical hold and re-initiation clinical development.

We use Finbox for our Source Data .

Please email editor@sectorreports.com.au for any edits or errors, or if you would like information on using our press release distribution service.

We will get back to you within 24 hours.

The post Novavax (NVAX) And CymaBay Therapeutics (CBAY) Hit 1-Week High On Account Of Affirmative Developments appeared first on The Market Signals .

COMTEX_365724227/2662/2020-05-14T11:29:50

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com . You can also contact MarketWatch Customer Service via our Customer Center .

/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 113.56
+11.12 +10.86%
Volume: 8.34M
Sept. 25, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$6.96 billion
Rev. per Employee
$90,470
loading...
/zigman2/quotes/201917619/composite
US : U.S.: Nasdaq
$ 6.51
+0.15 +2.36%
Volume: 985,300
Sept. 25, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$448.45 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/201917619/composite
US : U.S.: Nasdaq
$ 6.51
+0.15 +2.36%
Volume: 985,300
Sept. 25, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$448.45 million
Rev. per Employee
N/A
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.